MENUNews and Events
Recent Releases
04/28/2022 - 10:45am
Rogel Cancer Center announces new cancer health equity scholars, plus other 2022 awards
The University of Michigan Rogel Cancer Center will provide funding support to 12 exceptional faculty researchers, 2 early career clinical researchers and six medical and graduate students. In addition, the center has launched a new program for Rogel Scholars in Cancer Health Equity, to support two faculty members who are working to address the cancer burden in historically underserved or excluded populations.
Researchers use artificial intelligence to learn the effectiveness of bladder cancer treatment
By using an artificial intelligence-based system, researchers improved doctors' assessment of whether patients with bladder cancer had a complete response to chemotherapy before undergoing a radical cystectomy (bladder cancer removal surgery).
04/20/2022 - 3:30pm
Tumors partially destroyed with sound don’t come back
Noninvasive sound technology developed at the University of Michigan breaks down liver tumors in rats, kills cancer cells and spurs the immune system to prevent further spread—an advance that could lead to improved cancer outcomes in humans.
04/20/2022 - 3:15pm
Emerging Leaders set the agenda for next generation
The Emerging Leaders Council (ELC) is comprised of 15 early career faculty members interested in taking a larger role in the cancer center. Candidates are selected by the SLC and serve 3-year terms. The council is led by a chair, and two co-chairs elected by the ELC members to serve one-year terms.
04/12/2022 - 12:45pm
The importance of reducing heart exposure during radiation treatment
A team at the University of Michigan Health Rogel Cancer Center, in partnership with the statewide Michigan Radiation Oncology Quality Consortium, or MROQC, lung cancer collaborative, co-led by Shruti Jolly, M.D., and Peter Paximadis, M.D., of Spectrum Health Lakeland in St. Joseph, Michigan, found that raising awareness about the risk of radiation exposure to the heart and standardizing cardiac exposure limits reduced the average dose to the heart by 15% and reduced the number of patients receiving the highest heart doses by half without minimizing tumor treatment or increasing dosage to other at-risk organs in the chest.
Publications
